Medivation’s Dimebon Shines In Alzheimer’s Open-label Extension Study
Firm recently began confirmatory Phase III; expects to file in 2010 for mild-to-moderate Alzheimer’s.
Firm recently began confirmatory Phase III; expects to file in 2010 for mild-to-moderate Alzheimer’s.